Anavex Life Sciences Corp. (AVXL) Rating Reiterated by Maxim Group
Anavex Life Sciences Corp. (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by research analysts at Maxim Group in a research note issued on Tuesday. They presently have a $15.00 target price on the stock. Maxim Group’s price target suggests a potential upside of 277.83% from the company’s current price.
Separately, FBR & Co set a $10.00 target price on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Thursday, September 29th.
Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.97 on Tuesday. The company’s market capitalization is $141.77 million. The firm has a 50-day moving average of $3.23 and a 200 day moving average of $3.99. Anavex Life Sciences Corp. has a one year low of $2.43 and a one year high of $8.30.
TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/12/01/anavex-life-sciences-corp-avxl-rating-reiterated-by-maxim-group.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVXL. California State Teachers Retirement System boosted its position in Anavex Life Sciences Corp. by 1.0% in the third quarter. California State Teachers Retirement System now owns 69,164 shares of the company’s stock valued at $251,000 after buying an additional 700 shares during the last quarter. Rhumbline Advisers boosted its position in Anavex Life Sciences Corp. by 13.1% in the third quarter. Rhumbline Advisers now owns 35,476 shares of the company’s stock valued at $129,000 after buying an additional 4,100 shares during the last quarter. Credit Suisse AG boosted its position in Anavex Life Sciences Corp. by 28.6% in the third quarter. Credit Suisse AG now owns 65,937 shares of the company’s stock valued at $239,000 after buying an additional 14,660 shares during the last quarter. American International Group Inc. bought a new position in Anavex Life Sciences Corp. during the second quarter valued at $115,000. Finally, Nationwide Fund Advisors bought a new position in Anavex Life Sciences Corp. during the second quarter valued at $130,000. 12.83% of the stock is owned by hedge funds and other institutional investors.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Stock Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related stocks with our FREE daily email newsletter.